Search

Your search keyword '"Kaufmann, Scott H."' showing total 1,443 results
Start Over Author "Kaufmann, Scott H."
1,443 results on '"Kaufmann, Scott H."'

151. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Author

Kondrashova, Olga, Topp, Monique, Nesic, Ksenija, Lieschke, Elizabeth, Ho, Gwo-Yaw, Harrell, Maria I., Zapparoli, Giada V., Hadley, Alison, Holian, Robert, Boehm, Emma, Heong, Valerie, Sanij, Elaine, Pearson, Richard B., Krais, John J., Johnson, Neil, McNally, Orla, Ananda, Sumitra, Alsop, Kathryn, Hutt, Karla J., Kaufmann, Scott H., Lin, Kevin K., Harding, Thomas C., Traficante, Nadia, Australian Ovarian Cancer Study (AOCS), deFazio, Anna, McNeish, Iain A., Bowtell, David D., Swisher, Elizabeth M., Dobrovic, Alexander, Wakefield, Matthew J., and Scott, Clare L.

Published
2018
Full Text
View/download PDF

163. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Author

Karp, Judith E., Vener, Tatiana I., Raponi, Mitch, Ritchie, Ellen K., Smith, B. Douglas, Gore, Steven D., Morris, Lawrence E., Feldman, Eric J., Greer, Jacqueline M., Malek, Sami, Carraway, Hetty E., Ironside, Valerie, Galkin, Steven, Levis, Mark J., McDevitt, Michael A., Roboz, Gail R., Gocke, Christopher D., Derecho, Carlo, Palma, John, Wang, Yixin, Kaufmann, Scott H., Wright, John J., and Garret-Mayer, Elizabeth

Published
2012
Full Text
View/download PDF

165. Abstract 1832: CHK1 inhibitor prexasertib induces NOXA-dependent apoptosis in ovarian cancer

Author

Venkatachalam, Annapoorna, primary, Peterson, Kevin L., additional, Correia, Cristina, additional, Flatten, Karen S., additional, Hou, Xianon, additional, Schneider, Paula A., additional, Balczewski, Emily, additional, McGehee, Cordelia, additional, Hurley, Rachel M., additional, Meng, Xue W., additional, Sine, Chance, additional, Shah, Rameen, additional, Vincelettte, Nicole, additional, Ding, Husheng, additional, Li, Hu, additional, Weroha, Saravut (John), additional, and Kaufmann, Scott H., additional

Published
2022
Full Text
View/download PDF

166. Impact of Homologous Recombination Status and Responses With Veliparib Combined With First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study

Author

Swisher, Elizabeth M., primary, Aghajanian, Carol, additional, O'Malley, David M., additional, Fleming, Gini F., additional, Kaufmann, Scott H., additional, Levine, Douglas A., additional, Birrer, Michael J., additional, Moore, Kathleen N., additional, Spirtos, Nick M., additional, Shahin, Mark S., additional, Reid, Thomas J., additional, Friedlander, Michael, additional, Steffensen, Karina Dahl, additional, Okamoto, Aikou, additional, Sehgal, Vasudha, additional, Ansell, Peter J., additional, Dinh, Minh H., additional, Bookman, Michael A., additional, and Coleman, Robert L., additional

Published
2022
Full Text
View/download PDF

168. A Phase 1 and Pharmacodynamic Study of Chronically-Dosed, Single-Agent Veliparib (ABT-888) in Patients with BRCA1- or BRCA2-Mutated Cancer; Platinum-Refractory Ovarian or Triple-Negative Breast Cancer

Author

Manzo, Julia, Puhalla, Shannon, Pahuja, Shalu, Ding, Fei, Lin, Yan, Appleman, Leonard, Tawbi, Hussein, Stoller, Ronald, Lee, James J, Diergaarde, Brenda, Kiesel, Brian F., Yu, Jing, Tan, Antoinette R., Belani, Chandra P., Chew, Helen, Garcia, Agustin A., Morgan, Robert J., Hendrickson, Andrea E. Wahner, Visscher, Daniel W., Hurley, Rachel M., Kaufmann, Scott H., Swisher, Elizabeth M., Oesterreich, Steffi, Katz, Tiffany, Ji, Jiuping, Zhang, Yiping, Parchment, Ralph E., Chen, Alice, Duan, Wenrui, Giranda, Vincent, Shepherd, Stacie Peacock, Ivy, S. Percy, Chu, Edward, and Beumer, Jan H.

Subjects
BRCA2 Protein, Ovarian Neoplasms, BRCA1 Protein, Nausea, Triple Negative Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Article, Seizures, Lymphopenia, Antineoplastic Combined Chemotherapy Protocols, Humans, Benzimidazoles, Female, Platinum
Abstract

PURPOSE: BRCA1 or BRCA2 mutated cancers (BRCAmut) have intrinsic sensitivity to PARP inhibitors due to deficiency in homologous recombination-mediated DNA repair. There are similarities between BRCAmut and BRCAwt ovarian and basal-like breast cancers. This phase I study determined the recommended phase II dose (RP2D) and preliminary efficacy of the PARP inhibitor, veliparib (ABT-888), in these patients. PATIENTS AND METHODS: Patients (n=98) were dosed with veliparib 50–500 mg twice daily (BID). The BRCAmut cohort (n=70) contained predominantly ovarian (53%) and breast (23%) cancers; the BRCAwt cohort (n=28) consisted primarily of breast cancer (86%). The MTD, DLT, adverse events, PK, PD, and clinical response were assessed. RESULTS: DLTs were grade 3 nausea/vomiting at 400 mg BID in a BRCAmut carrier, grade 2 seizure at 400 mg BID in a patient with BRCAwt cancer, and grade 2 seizure at 500 mg BID in a BRCAmut carrier. Common toxicities included nausea (65%), fatigue (45%), and lymphopenia (38%). Grade 3/4 toxicities were rare (highest lymphopenia at 15%). Overall response rate (ORR) was 23% (95% CI 13%−35%) in BRCAmut overall, and 37% (95% CI 21%−55%) at 400 mg BID and above. In BRCAwt, ORR was 8% (95% CI 1%−26%), and clinical benefit rate was 16% (95% CI 4%−36%), reflecting prolonged stable disease in some patients. PK was linear with dose and was correlated with response and nausea. CONCLUSIONS: Continuous veliparib is safe and tolerable. The RP2D was 400 mg BID. There is evidence of clinical activity of veliparib in patients with BRCAmut and BRCAwt cancers.

Published
2022

170. Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors

Author

Koch Institute for Integrative Cancer Research at MIT, Harvard University--MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology. Department of Materials Science and Engineering, Cotler, Max J, Ramadi, Khalil B, Hou, Xiaonan, Christodoulopoulos, Elena, Ahn, Sebastian, Bashyam, Ashvin, Ding, Huiming, Larson, Melissa, Oberg, Ann L, Whittaker, Charles, Jonas, Oliver, Kaufmann, Scott H, Weroha, S John, Cima, Michael J, Koch Institute for Integrative Cancer Research at MIT, Harvard University--MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology. Department of Materials Science and Engineering, Cotler, Max J, Ramadi, Khalil B, Hou, Xiaonan, Christodoulopoulos, Elena, Ahn, Sebastian, Bashyam, Ashvin, Ding, Huiming, Larson, Melissa, Oberg, Ann L, Whittaker, Charles, Jonas, Oliver, Kaufmann, Scott H, Weroha, S John, and Cima, Michael J

Abstract

Long-term treatment outcomes for patients with high grade ovarian cancers have not changed despite innovations in therapies. There is no recommended assay for predicting patient response to second-line therapy, thus clinicians must make treatment decisions based on each individual patient. Patient-derived xenograft (PDX) tumors have been shown to predict drug sensitivity in ovarian cancer patients, but the time frame for intraperitoneal (IP) tumor generation, expansion, and drug screening is beyond that for tumor recurrence and platinum resistance to occur, thus results do not have clinical utility. We describe a drug sensitivity screening assay using a drug delivery microdevice implanted for 24 h in subcutaneous (SQ) ovarian PDX tumors to predict treatment outcomes in matched IP PDX tumors in a clinically relevant time frame. The SQ tumor response to local microdose drug exposure was found to be predictive of the growth of matched IP tumors after multi-week systemic therapy using significantly fewer animals (10 SQ vs 206 IP). Multiplexed immunofluorescence image analysis of phenotypic tumor response combined with a machine learning classifier could predict IP treatment outcomes against three second-line cytotoxic therapies with an average AUC of 0.91.

Published
2022

171. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study

Author

Swisher, Elizabeth M, Aghajanian, Carol, O'Malley, David M, Fleming, Gini F, Kaufmann, Scott H, Levine, Douglas A, Birrer, Michael J, Moore, Kathleen N, Spirtos, Nick M, Shahin, Mark S, Reid, Thomas J, Friedlander, Michael, Steffensen, Karina Dahl, Okamoto, Aikou, Sehgal, Vasudha, Ansell, Peter J, Dinh, Minh H, Bookman, Michael A, Coleman, Robert L, Swisher, Elizabeth M, Aghajanian, Carol, O'Malley, David M, Fleming, Gini F, Kaufmann, Scott H, Levine, Douglas A, Birrer, Michael J, Moore, Kathleen N, Spirtos, Nick M, Shahin, Mark S, Reid, Thomas J, Friedlander, Michael, Steffensen, Karina Dahl, Okamoto, Aikou, Sehgal, Vasudha, Ansell, Peter J, Dinh, Minh H, Bookman, Michael A, and Coleman, Robert L

Abstract

Objective: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker status. Here, we report exploratory analyses of the impact of homologous recombination deficient (HRD) or proficient (HRP) status on progression-free survival (PFS) and objective response rates during chemotherapy. Methods: Women with Stage III-IV ovarian carcinoma were randomized to veliparib-throughout, veliparib-combination-only, or placebo. Stratification factors included timing of surgery and germline BRCA mutation status. HRD status was dichotomized at genomic instability score 33. During combination therapy, CA-125 levels were measured at baseline and each cycle; radiographic responses were assessed every 9 weeks. Results: Of 1140 patients randomized, 742 had BRCA wild type (BRCAwt) tumors (HRP, n = 373; HRD/BRCAwt, n = 329). PFS hazard ratios between veliparib-throughout versus control were similar in both BRCAwt populations (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; 95% confidence interval [CI] 0.53-1.09; HRP: 15.0 vs 11.5 months; hazard ratio 0.765; 95% CI 0.56-1.04). By Cycle 3, the proportion with ≥90% CA-125 reduction from baseline was higher in those receiving veliparib (pooled arms) versus control (34% vs 23%; P = 0.0004); particularly in BRCAwt and HRP subgroups. Complete response rates among patients with measurable disease after surgery were 24% with veliparib (pooled arms) and 18% with control. Conclusions: These results potentially broaden opportunities for PARPi utilization among patients who would not qualify for frontline PARPi maintenance based on other trials.

Published
2022

174. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

Author

Witzig, Thomas E., Tang, Hui, Micallef, Ivana N.M., Ansell, Stephen M., Link, Brian K., Inwards, David J., Porrata, Luis F., Johnston, Patrick B., Colgan, Joseph P., Markovic, Svetomir N., Nowakowski, Grzegorz S., Thompson, Carrie A., Allmer, Cristine, Maurer, Matthew J., Gupta, Mamta, Weiner, George, Hohl, Ray, Kurtin, Paul J., Ding, Husheng, Loegering, David, Schneider, Paula, Peterson, Kevin, Habermann, Thomas M., and Kaufmann, Scott H.

Published
2011
Full Text
View/download PDF

179. Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer

Author

Ray, Upasana, primary, Jung, Deok-Beom, additional, Jin, Ling, additional, Xiao, Yinan, additional, Dasari, Subramanyam, additional, Sarkar Bhattacharya, Sayantani, additional, Thirusangu, Prabhu, additional, Staub, Julie K., additional, Roy, Debarshi, additional, Roy, Bhaskar, additional, Weroha, S. John, additional, Hou, Xiaonan, additional, Purcell, James W., additional, Bakkum-Gamez, Jamie N., additional, Kaufmann, Scott H., additional, Kannan, Nagarajan, additional, Mitra, Anirban K., additional, and Shridhar, Viji, additional

Published
2022
Full Text
View/download PDF

186. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

Author

Chowdhury, Shrabanti, Kennedy, Jacob J., Ivey, Richard G., Murillo, Oscar D., Hosseini, Noshad, Song, Xiaoyu, Petralia, Francesca, Calinawan, Anna, Savage, Sara R., Berry, Anna B., Reva, Boris, Ozbek, Umut, Krek, Azra, Ma, Weiping, da Veiga Leprevost, Felipe, Ji, Jiayi, Yoo, Seungyeul, Lin, Chenwei, Voytovich, Uliana J., Huang, Yajue, Lee, Sun-Hee, Bergan, Lindsay, Lorentzen, Travis D., Mesri, Mehdi, Rodriguez, Henry, Hoofnagle, Andrew N., Herbert, Zachary T., Nesvizhskii, Alexey I., Zhang, Bing, Whiteaker, Jeffrey R., Fenyo, David, McKerrow, Wilson, Wang, Joshua, Schürer, Stephan C., Stathias, Vasileios, Chen, X. Steven, Barcellos-Hoff, Mary Helen, Starr, Timothy K., Winterhoff, Boris J., Nelson, Andrew C., Mok, Samuel C., Kaufmann, Scott H., Drescher, Charles, Cieslik, Marcin, Wang, Pei, Birrer, Michael J., and Paulovich, Amanda G.

Published
2024
Full Text
View/download PDF

191. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Author

Swisher, Elizabeth M., primary, Kristeleit, Rebecca S., additional, Oza, Amit M., additional, Tinker, Anna V., additional, Ray-Coquard, Isabelle, additional, Oaknin, Ana, additional, Coleman, Robert L., additional, Burris, Howard A., additional, Aghajanian, Carol, additional, O'Malley, David M., additional, Leary, Alexandra, additional, Welch, Stephen, additional, Provencher, Diane, additional, Shapiro, Geoffrey I., additional, Chen, Lee-may, additional, Shapira-Frommer, Ronnie, additional, Kaufmann, Scott H., additional, Goble, Sandra, additional, Maloney, Lara, additional, Kwan, Tanya, additional, Lin, Kevin K., additional, and McNeish, Iain A., additional

Published
2021
Full Text
View/download PDF

192. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer

Author

Huang, Dongqing, primary, Chowdhury, Shrabanti, additional, Wang, Hong, additional, Savage, Sara R., additional, Ivey, Richard G., additional, Kennedy, Jacob J., additional, Whiteaker, Jeffrey R., additional, Lin, Chenwei, additional, Hou, Xiaonan, additional, Oberg, Ann L., additional, Larson, Melissa C., additional, Eskandari, Najmeh, additional, Delisi, Davide A., additional, Gentile, Saverio, additional, Huntoon, Catherine J., additional, Voytovich, Uliana J., additional, Shire, Zahra J., additional, Yu, Qing, additional, Gygi, Steven P., additional, Hoofnagle, Andrew N., additional, Herbert, Zachary T., additional, Lorentzen, Travis D., additional, Calinawan, Anna, additional, Karnitz, Larry M., additional, Weroha, S. John, additional, Kaufmann, Scott H., additional, Zhang, Bing, additional, Wang, Pei, additional, Birrer, Michael J., additional, and Paulovich, Amanda G., additional

Published
2021
Full Text
View/download PDF

193. Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib

Author

Kwan, Tanya T., primary, Oza, Amit M., additional, Tinker, Anna V., additional, Ray-Coquard, Isabelle, additional, Oaknin, Ana, additional, Aghajanian, Carol, additional, Lorusso, Domenica, additional, Colombo, Nicoletta, additional, Dean, Andrew, additional, Weberpals, Johanne, additional, Severson, Eric, additional, Vo, Lan-Thanh, additional, Goble, Sandra, additional, Maloney, Lara, additional, Harding, Thomas, additional, Kaufmann, Scott H., additional, Ledermann, Jonathan A., additional, Coleman, Robert L., additional, McNeish, Iain A., additional, Lin, Kevin K., additional, and Swisher, Elizabeth M., additional

Published
2021
Full Text
View/download PDF

194. CHFR and Paclitaxel Sensitivity of Ovarian Cancer

Author

Wahner Hendrickson, Andrea E., primary, Visscher, Daniel W., additional, Hou, Xiaonan, additional, Goergen, Krista M., additional, Atkinson, Hunter J., additional, Beito, Thomas G., additional, Negron, Vivian, additional, Lingle, Wilma L., additional, Bruzek, Amy K., additional, Hurley, Rachel M., additional, Wagner, Jill M., additional, Flatten, Karen S., additional, Peterson, Kevin L, additional, Schneider, Paula A, additional, Larson, Melissa C., additional, Maurer, Matthew J., additional, Kalli, Kimberly R., additional, Oberg, Ann L., additional, Weroha, S. John, additional, and Kaufmann, Scott H., additional

Published
2021
Full Text
View/download PDF

195. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

Author

Kanakkanthara, Arun, primary, Hou, Xiaonan, additional, Ekstrom, Thomas L., additional, Zanfagnin, Valentina, additional, Huehls, Amelia M., additional, Kelly, Rebecca L., additional, Ding, Husheng, additional, Larson, Melissa C., additional, Vasmatzis, George, additional, Oberg, Ann L., additional, Kaufmann, Scott H., additional, Mansfield, Aaron S., additional, Weroha, S. John, additional, and Karnitz, Larry M., additional

Published
2021
Full Text
View/download PDF

196. A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)

Author

Guru Murthy, Guru Subramanian, primary, Kaufmann, Scott H., additional, Szabo, Aniko, additional, Harrington, Alexandra M., additional, Michaelis, Laura C., additional, Abedin, Sameem, additional, Carlson, Karen, additional, Runaas, Lyndsey, additional, Longo, Walter L., additional, Hinman, Alexander, additional, Maldonado-Schmidt, Sonia, additional, Thomas, Althea, additional, Baim, Arielle, additional, Litzow, Mark R., additional, and Atallah, Ehab L., additional

Published
2021
Full Text
View/download PDF

197. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Author

Saliba, Antoine N., Kaufmann, Scott H., Stein, Eytan M., Patel, Prapti A., Baer, Maria R., Stock, Wendy, Deininger, Michael, Blum, William, Schiller, Gary J., Olin, Rebecca L., Litzow, Mark R., Lin, Tara L., Ball, Brian J., Boyiadzis, Michael M., Traer, Elie, Odenike, Olatoyosi, Arellano, Martha L., Walker, Alison, Duong, Vu H., Kovacsovics, Tibor, Collins, Robert H., Shoben, Abigail B., Heerema, Nyla A., Foster, Matthew C., Peterson, Kevin L., Schneider, Paula A., Martycz, Molly, Gana, Theophilus J., Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O., Chen, Timothy, Stefanos, Mona, Mims, Alice S., Borate, Uma, Burd, Amy, Druker, Brian J., Levine, Ross L., Byrd, John C., and Foran, James M.

Published
2023
Full Text
View/download PDF

200. TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer

Author

Chien, Jeremy, Sicotte, Hugues, Fan, Jian-Bing, Humphray, Sean, Cunningham, Julie M., Kalli, Kimberly R., Oberg, Ann L., Hart, Steven N., Li, Ying, Davila, Jaime I., Baheti, Saurabh, Wang, Chen, Dietmann, Sabine, Atkinson, Elizabeth J., Asmann, Yan W., Bell, Debra A., Ota, Takayo, Tarabishy, Yaman, Kuang, Rui, Bibikova, Marina, Cheetham, Keira R., Grocock, Russell J., Swisher, Elizabeth M., Peden, John, Bentley, David, Kocher, Jean-Pierre A., Kaufmann, Scott H., Hartmann, Lynn C., Shridhar, Viji, and Goode, Ellen L.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results